

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 26, 2025

Anteris Technologies Global Corp.
(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation)	001-42437 (Commission File Number)	99-1407174 (I.R.S. Employer Identification No.)
Toowong Tower, Level 3, Suite 302 9 Sherwood Road Toowong, QLD Australia (Address of Principal Executive Offices)		4066 (Zip Code)

Registrant's telephone number, including area code: +61 7 3152 3200

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.0001 per share	AVR	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.02. Termination of a Material Definitive Agreement.

On November 26, 2025, Anteris Technologies Global Corp. (the “Company”) notified 4C Medical Technologies, Inc. (“4C”) that it was not renewing the Second Amended and Restated Supply and License Agreement, as amended (the “Supply Agreement”), between the Company and 4C, which provided for the supply by the Company to 4C of ADAPT[®] tissue used in 4C’s production of medical devices related to transcatheter mitral valve and tricuspid valve regurgitation therapy and granted a limited license to the Company’s related sterilization methods in connection with use of ADAPT[®] tissue by 4C in its production of medical devices.

The Supply Agreement had a term expiring on June 1, 2026, at which time it would automatically renew for successive one-year terms unless either party provided written notice of non-renewal 180 days prior thereto. The Company will not incur any early termination penalties in connection with its non-renewal of the Supply Agreement. The termination of this contract does not materially impact on the financial results of the Company.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Anteris Technologies Global Corp.

Date: December 1, 2025

By: /s/ Wayne Paterson

Name: Wayne Paterson

Title: Vice Chairman and Chief Executive Officer
